Trial Profile
Sitagliptin (JANUVIA) Post Marketing Surveillance Protocol.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jun 2012 Actual patient number 2974 added as reported by ClinicalTrials.gov.
- 19 May 2011 New trial record